Spots Global Cancer Trial Database for Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Official Title: A Phase II, Multi-center, Single-arm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K δ/γ, and SIK3 Inhibitor, in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Study ID: NCT06189209
Conditions
Interventions
Study Description
Brief Summary: This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
HCG City Cancer Center, Vijayawada, Andhra Pradesh, India
Narayana Hrudayala Majumdar Shaw Hospital, Bangalore, Karnataka, India
Tata Memorial Centre, Mumbai, Maharashtra, India
Mumbai Oncocare Centre, Mumbai, Maharashtra, India
Sahyadri Super Speciality Hospital, Pune, Maharashtra, India
Meenakshi Mission Hospital & Research Center, Madurai, Tamil Nadu, India
Nizams Institute of Medical Science, Hyderabad, Telangana, India
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
